Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 1Metastatic Hormone Refractory Prostate Cancer 1

Interventions

pembrolizumab 1024Carboplatin 966Paclitaxel 933Gemcitabine 794Cisplatin 753Docetaxel 684Bevacizumab 609Pemetrexed 504Nivolumab 487Cyclophosphamide 474Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 373Oxaliplatin 348Injections 347atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 246Doxorubicin 241Ipilimumab 226fludarabine 220Lenalidomide 220Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × danusertib × Clear all
NCT00766324 2014-05-28

PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

Nerviano Medical Sciences

Phase 2 Completed
118 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

NCT00872300 2014-05-28

PHA-739358 for the Treatment of Multiple Myeloma

Nerviano Medical Sciences

Phase 2 Terminated
7 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡